BioNTech updated Phase 3 shows gotistobart improved lung cancer overall survival

 

BioNTech reports updated Phase 3 PRESERVE-003 data showing CTLA-4 antibody gotistobart improved overall survival to 18.5 vs 10 months with docetaxel

• Updated Phase 3 PRESERVE-003 stage 1 trial evaluated gotistobart (BNT316/ONC-392) versus docetaxel in previously treated squamous NSCLC
• Gotistobart showed manageable safety profile in the updated Phase 3 PRESERVE-003 stage 1 data

https://finviz.com/stock?t=BNTX&p=d